Is pandrug-resistance in A. baumannii a transient phenotype? Epidemiological clues from a 4-year cohort study at a tertiary referral hospital in Greece

J Chemother. 2021 Sep;33(5):354-357. doi: 10.1080/1120009X.2020.1839689. Epub 2020 Oct 30.

Abstract

Pandrug-resistant A. baumannii (PDRAB) is increasingly being reported but remains rare. Several case studies show that A. baumannii can acquire resistance to last resort antibiotics during treatment by single-step chromosomal mutations. However, re-emergence of the ancestral susceptible strain after withdrawal of antibiotics has been described, possibly due to fitness cost associated with acquired resistance. Therefore, PDRAB may be a transient phenotype. Epidemiological data to show this process in larger cohorts are currently lacking. In this study of 91 hospitalized patients with PDRAB we showed the frequent (60%) isolation of non-PDRAB, often susceptible only to colistin, aminoglycosides and/or tigecycline, preceding and/or following PDRAB isolation. However, the isolation of PDRAB in two outpatients, 25 and 36 days after their discharge from the hospital, suggests the potential of some PDRAB strains to persist even in the absence of antimicrobial pressure.

Keywords: Acinetobacter baumannii; PDR; epidemiology; pandrug-resistant; resistance.

MeSH terms

  • Acinetobacter Infections / epidemiology*
  • Acinetobacter Infections / microbiology
  • Acinetobacter baumannii / isolation & purification*
  • Aged
  • Anti-Bacterial Agents
  • Cross Infection
  • Drug Resistance, Multiple, Bacterial / physiology*
  • Female
  • Greece
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Tertiary Care Centers

Substances

  • Anti-Bacterial Agents